Although current data argue against an increased risk of pancreatic cancer and thyroid cancer with semaglutide, it can be debated whether the background incidence of these disorders is too low to fully conclude the absence of an association
[171] A 2025 observational study reported a modest increased risk of a serious eye condition in people with diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists
Novo Nordisks internal communications, safety databases, and regulatory submissions contain the evidence needed to prove knowledge of gastroparesis and NAION risks, but extracting and presenting this information requires legal teams with experience handling massive pharmaceutical discovery
Dosing schedules vary by individual, medical history, and prescriber judgment no calculator or article should be treated as a substitute for that guidance
What should you look for on the Wegovy label
GLP-1 patches are also in development, promising needle-free delivery with pre-measured doses